Loading stock data…
CATX
$2.96+0.03 (+1.19%)
Market OpenUpdated 3:55 PM EDT
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Perspective Therapeutics, Inc. in the Healthcare sector is trading at $2.96. Wall Street consensus targets $12.93 (15 analysts), implying a +336.2% move over the next 12 months. The stock is currently 52% below its 52-week high of $6.16, remaining 17.9% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +336.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.96
Potential Downside
0%
Whystock Fair Value$2.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$12.93+336.2%
Range$6.00 – $18.00
Fundamentals
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.99%
Volume
Today's trading volume
1.30M
Recent News
Perspective Therapeutics doses first brain tumor patient in expanded radiopharmaceutical trial
Perspective Therapeutics Inc. (NYSE-A:CATX) has treated the first patient with a type of brain tumor called meningioma using its experimental drug [212Pb]VMT-a-NET, broadening a clinical trial that previously focused only on a different cancer type known as neuroendocrine tumors. The new arm...
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress
Perspective Therapeutics Inc. (NYSE:CATX) is one of the best high-return penny stocks to buy right now. On February 2, Perspective Therapeutics Inc. (NYSE:CATX) priced an underwritten offering of 39.57 million shares at $3.78 per share. The company anticipates gross proceeds of $175 million from the offering. It plans to use the net proceeds from the […]
Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed?
Perspective Therapeutics recently completed a US$174.99 million follow-on equity offering, issuing 39,576,088 shares of common stock at US$3.79 and 6,598,046 pre-funded warrants at US$3.789, as it works to advance its cancer-focused targeted alpha therapies program. This capital raise follows encouraging interim Phase 1/2a data for lead candidate VMT-α-NET using the alpha-emitting isotope Lead-212, which has drawn increased attention from the oncology and investment communities. We will now...
A Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline Updates
Perspective Therapeutics (CATX) drew fresh attention after updated interim data from its Phase 1/2a VMT-a-NET trial showed sustained anti-tumor activity, along with a business update on pipeline priorities and manufacturing expansion plans. See our latest analysis for Perspective Therapeutics. The recent VMT-a-NET update arrived after a sharp rise in the share price, with a 39.85% 7-day share price return and a 45.77% 90-day share price return. Meanwhile, the 1-year total shareholder return...